TPBG
ABBV icon

Turning Point Benefit Group’s AbbVie ABBV Stock Holding History

Turning Point Benefit Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-884
Closed -$202K – 99
2025
Q4 		$202K Buy
884
+13
+1% +$2.96K 0.11% 89
2025
Q3 		$213K Buy
+871
New +$177K 0.13% 82

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Turning Point Benefit Group's ABBV Position: Q1 2026 in Review

Turning Point Benefit Group sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 884 shares — an estimated $202K sold.

Turning Point Benefit Group first reported a position in ABBV in Q3 2025 and held it in 2 quarters. The position peaked at $213K in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Turning Point Benefit Group reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 884 AbbVie shares in Q1 2026, an estimated $202K.
  • Turning Point Benefit Group first reported a position in AbbVie in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's AbbVie position peaked at $213K in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.